Quantum Private Wealth LLC Sells 53 Shares of Stryker Co. (NYSE:SYK)

Quantum Private Wealth LLC trimmed its holdings in Stryker Co. (NYSE:SYK) by 4.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,092 shares of the medical technology company’s stock after selling 53 shares during the period. Quantum Private Wealth LLC’s holdings in Stryker were worth $327,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Tyche Wealth Partners LLC acquired a new position in Stryker in the 4th quarter worth $417,000. HealthInvest Partners AB acquired a new position in shares of Stryker during the fourth quarter worth about $3,834,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Stryker by 103.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 120,707 shares of the medical technology company’s stock worth $36,147,000 after buying an additional 61,438 shares in the last quarter. Wealth Alliance raised its position in Stryker by 3.4% in the 4th quarter. Wealth Alliance now owns 2,156 shares of the medical technology company’s stock valued at $646,000 after buying an additional 71 shares during the last quarter. Finally, Octavia Wealth Advisors LLC lifted its stake in Stryker by 11.2% in the 4th quarter. Octavia Wealth Advisors LLC now owns 1,633 shares of the medical technology company’s stock valued at $490,000 after acquiring an additional 165 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Transactions at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now directly owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 212,109 shares of company stock valued at $72,845,768. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and lifted their price objective for the company from $315.00 to $360.00 in a report on Wednesday, January 31st. Wells Fargo & Company lifted their price target on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Evercore ISI lifted their target price on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, TD Cowen increased their price target on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $339.22.

Stryker Stock Performance

Shares of NYSE:SYK traded down $1.47 on Wednesday, reaching $337.66. 1,239,358 shares of the company’s stock were exchanged, compared to its average volume of 925,865. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company has a fifty day moving average of $350.70 and a 200-day moving average of $311.86. The company has a market capitalization of $128.47 billion, a price-to-earnings ratio of 40.91, a PEG ratio of 2.73 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the business earned $3.00 earnings per share. Stryker’s revenue was up 11.8% on a year-over-year basis. On average, research analysts predict that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.95%. Stryker’s payout ratio is 38.79%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.